EPCAM and breast cancer: Similarly, EpCAM upregulation of AKT downstream targets promotes stemness and DNA loss repair in breast cancer cells, thereby enhancing resistance to radiotherapy and DNA-damaging chemotherapeutic agents (such as doxorubicin, cisplatin, or gemcitabine) [141].